AMPE - Ampio surges 7.5% on phase 1 data for COVID-19 respiratory treatment

Shares of Ampio Pharmaceuticals (AMPE) are up 7.5% to $1.95 in morning trading after the company reported preliminary positive phase 1 results for AP-014, an inhaled treatment for respiratory distress in patients with COVID-19.AP-014 is testing an inhaled version of the company's Ampion, which is described as a "novel biologic drug containing a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease."Preliminary results for inhaled Ampion demonstrated an 8% all-cause mortality rate in the treatment group compared to 21% in standard of care alone.Average hospital stay was seven days for the Ampion group compared to 11 days for standard of care patients.By day five, 86% of patients who received Ampion were stable or had improvement compared to 75% of standard of care patients.Adverse events were similar between the two groups, and no serious drug-related adverse events were reported.

For further details see:

Ampio surges 7.5% on phase 1 data for COVID-19 respiratory treatment